147 related articles for article (PubMed ID: 9835860)
1. [Preclinical evaluation of anticancer drugs: a model remaining a model!].
Lavelle F
Bull Cancer; 1998 Oct; 85(10):837-42. PubMed ID: 9835860
[TBL] [Abstract][Full Text] [Related]
2. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development.
Kelland LR
Eur J Cancer; 2004 Apr; 40(6):827-36. PubMed ID: 15120038
[TBL] [Abstract][Full Text] [Related]
3. Human tumor xenografts in the nude mouse and their value as test models in anticancer drug development (review).
Winograd B; Boven E; Lobbezoo MW; Pinedo HM
In Vivo; 1987; 1(1):1-13. PubMed ID: 2979758
[TBL] [Abstract][Full Text] [Related]
4. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development.
Peterson JK; Houghton PJ
Eur J Cancer; 2004 Apr; 40(6):837-44. PubMed ID: 15120039
[TBL] [Abstract][Full Text] [Related]
5. 50 years of preclinical anticancer drug screening: empirical to target-driven approaches.
Suggitt M; Bibby MC
Clin Cancer Res; 2005 Feb; 11(3):971-81. PubMed ID: 15709162
[TBL] [Abstract][Full Text] [Related]
6. Experimental design for the evaluation of the antitumor action of cytokines.
Ciolli V; Sestili P; Brigato M; Gabriele L; Varano F; Locardi C; Belardelli F
Ann Ist Super Sanita; 1990; 26(3-4):441-51. PubMed ID: 2091505
[TBL] [Abstract][Full Text] [Related]
7. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy.
Hoffman RM
Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987
[TBL] [Abstract][Full Text] [Related]
8. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages.
Bibby MC
Eur J Cancer; 2004 Apr; 40(6):852-7. PubMed ID: 15120041
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
10. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
Frijhoff AF; Conti CJ; Senderowicz AM
Mol Carcinog; 2004 Apr; 39(4):183-94. PubMed ID: 15057870
[TBL] [Abstract][Full Text] [Related]
11. Role of murine tumor models in cancer treatment research.
Martin DS; Balis ME; Fisher B; Frei E; Freireich EJ; Heppner GH; Holland JF; Houghton JA; Houghton PJ; Johnson RK
Cancer Res; 1986 Apr; 46(4 Pt 2):2189-92. PubMed ID: 3948188
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of poly(L-glutamic acid)-paclitaxel on syngeneic and xenografted tumors.
Li C; Price JE; Milas L; Hunter NR; Ke S; Yu DF; Charnsangavej C; Wallace S
Clin Cancer Res; 1999 Apr; 5(4):891-7. PubMed ID: 10213226
[TBL] [Abstract][Full Text] [Related]
13. Genetically engineered models have advantages over xenografts for preclinical studies.
Becher OJ; Holland EC
Cancer Res; 2006 Apr; 66(7):3355-8, discussion 3358-9. PubMed ID: 16585152
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of ZD1694 (tomudex) against human head and neck cancer in nude mouse models: role of dosing schedule and plasma thymidine.
Cao S; McGuire JJ; Rustum YM
Clin Cancer Res; 1999 Jul; 5(7):1925-34. PubMed ID: 10430100
[TBL] [Abstract][Full Text] [Related]
15. New anticancer agents: in vitro and in vivo evaluation.
Zips D; Thames HD; Baumann M
In Vivo; 2005; 19(1):1-7. PubMed ID: 15796152
[TBL] [Abstract][Full Text] [Related]
16. Use of a surrogate marker (human secreted alkaline phosphatase) to monitor in vivo tumor growth and anticancer drug efficacy in ovarian cancer xenografts.
Bao R; Selvakumaran M; Hamilton TC
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):373-9. PubMed ID: 10985897
[TBL] [Abstract][Full Text] [Related]
17. Testing therapeutic potency of anticancer drugs in animal studies: a commentary.
Den Otter W; Steerenberg PA; Van der Laan JW
Regul Toxicol Pharmacol; 2002 Apr; 35(2 Pt 1):266-72. PubMed ID: 12052010
[TBL] [Abstract][Full Text] [Related]
18. Screening and evaluation of anticancer agents.
Zee-Cheng RK; Cheng CC
Methods Find Exp Clin Pharmacol; 1988 Feb; 10(2):67-101. PubMed ID: 3283480
[TBL] [Abstract][Full Text] [Related]
19. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
Hansen K; Khanna C
Eur J Cancer; 2004 Apr; 40(6):858-80. PubMed ID: 15120042
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
Breistøl K; Balzarini J; Sandvold ML; Myhren F; Martinsen M; De Clercq E; Fodstad O
Cancer Res; 1999 Jun; 59(12):2944-9. PubMed ID: 10383159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
